Copd Patient Articles & Analysis
18 news found
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. Despite extensive research, translating findings from bench to bedside remains a challenge. Precision Cut Lung Slices (PCLS) have emerged as a versatile tool in COPD research, offering unique advantages for understanding disease mechanisms and ...
Having a treatment that can help patients breathe easier and live a better quality of life, without surgical intervention, will be a major step forward in COPD care in Japan.” Over 600,000 Japanese patients suffer from severe COPD, including approximately 100,000 patients with severe disease where ...
(NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
The AeriSeal System is used to close collateral air channels in a target lung lobe of a patient with severe COPD/emphysema, making the patient eligible to then undergo Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Valves. ...
According to WHO, the demonstration of irreversible airway obstruction is essential for diagnosing chronic obstructive pulmonary disease (COPD), which is the third leading cause of death worldwide. It is estimated that up to 67–81% of patients with COPD remain undiagnosed. Mobile phone-linked spirometers can be used almost anywhere – ...
ByAioCare
ALung has initiated commercial development of the next generation Hemolung RAS to provide clinicians with the flexibility to support patients across the full spectrum of acute and acute-on-chronic respiratory failure using a single integrated device. ...
The ASCENT study was conducted in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) and cardiovascular disease and / or significant cardiovascular risk factors. This patient population is of particular relevance as cardiovascular disease is the most common and significant comorbidity of COPD, with ...
The ASCENT study was conducted in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) and cardiovascular disease and / or significant cardiovascular risk factors. This patient population is of particular relevance as cardiovascular disease is the most common and significant comorbidity of COPD, with ...
Steve Harris, Circassia’s Chief Executive, said: “We are delighted with the FDA approval of Duaklir®, which we believe will provide a valuable treatment option for the significant number of patients with COPD in the United States. The addition of Duaklir® to our portfolio further strengthens our range of marketed respiratory products and we ...
Tudorza®’s expanded label now includes data from the phase IV ASCENT study, which was conducted in patients with moderate to very severe COPD and cardiovascular disease and / or significant cardiovascular risk factors. The study demonstrated that Tudorza® is effective at reducing COPD exacerbations with no increase in major ...
Tudorza®’s expanded label now includes data from the phase IV ASCENT study, which was conducted in patients with moderate to very severe COPD and cardiovascular disease and / or significant cardiovascular risk factors. ...
We believe that based on its broad clinical database, Duaklir®, if approved, has the potential to become an important new treatment option for COPD patients in the United States. In addition, the inclusion of clinical data in Tudorza®’s prescribing information demonstrating cardiovascular safety and reductions in COPD ...
We believe that Duaklir®, if approved, has the potential to provide an important treatment option for the significant number of patients with COPD in the United States. In addition, the positive cardiovascular safety and COPD exacerbation reduction results achieved in the Tudorza® ASCENT study offer the potential to include unique new ...
Cardiovascular disease is the most common and significant comorbidity of COPD, with approximately 30% of COPD patients dying from cardiovascular conditions. ...
The CHROMED trial, one of the largest clinical trial using FOT to monitor remotely COPD patients and prevent exacerbation has now been published on the American Journal of Respiratory and Critical care medicine! Using the RESMON PRO DIARY (the home version of the well proven, hospital, clinical unit, the RESMON PRO FULL), 312 patients from 5 ...
RESTECH srl and VIVISOL has established a long-term commercial partnership to commercialize the RESMON PRO DIARY and its innovative algorithm for the detection of the risk of exacerbation in COPD patients. Thanks to this collaboration RESTECH will be able to consolidate its operative know-how and bring the latest innovations in home monitoring directly in the ...
Restech, in its role of technical manager and together with all the partner of the project, successfully concluded the CHROMED trial. With 312 patients enrolled and studied for 9 months by 6 clinical centers in 5 EU Countries, CHROMED has been the largest international multi-center randomized control trial evaluating the effectiveness of an integrated telecare approach for ...
Details of a framework that would hook into networks of sensors and provide patients with timely alerts are reported this month in the International Journal of Computational Intelligence Studies. Ioannis Kouris and Dimitris Koutsouris of the National Technical University of Athens, explain that patients with chronic obstructive pulmonary disease ...